GL1X · GenesisL1 explorer

MolNFT v1 · #137074 · protein

Crystal structure of human MYT1 kinase domain in complex with bosutinib

5VCY · Membrane-associated tyrosine- and threonine-specific CDC2…: “Crystal structure of human MYT1 kinase domain in complex with bosutinib”. X-ray diffraction, 1 ligand (DB8), 3 pockets (best druggability 0.69). MolNFT v1 #137074 on…

PDB
5VCY
Type
protein
Length
296 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Membrane-associated tyrosine- and threonine-specific CDC2- inhibitory kinase
EC
2.7.11.1
UniProt
Q99640
Ligands
DB8
Pockets
3 · best druggability 0.69

Structure

x-ray diffraction · 1 distinct chain · 38% helix, 18% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AMembrane-associated tyrosine- and threonine-specific CDC2- inhibitory kinase (EC 2.7.11.1)protein29638% helix, 18% strandQ99640

Ligands and binding sites

  • DB8 · 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile · ligand · chains A
  • EDO · 1,2-ethanediol · additive · 3 copies · chains A
  • PEG · Di(hydroxyethyl)ether · additive · chains A
  • DMS · Dimethyl sulfoxide · additive · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
14420.690.8042DB8, DMS
21940.480.7628empty
3670.380.7918empty

Compared structures

  • 5VCY · Crystal structure of human MYT1 kinase domain in complex with bosutinib · the same entry in another collection · chain A against A, TM-score 1.00
  • Q99640 · AlphaFold monomer V2.0 prediction for membrane-associated tyrosine- and… · a predicted model of the same protein · chain A against A, TM-score 0.97

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.